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In this manuscript, an E1 and E3 deleted adenoviral recombinant expressing the rabies virus glycoprotein (G protein)
under the control of the cytomegalovirus early promoter was tested for induction of a rabies virus-specific immune response
in mice. The construct was found to induce neutralizing antibodies and cytolytic T cells to rabies virus. Mice vaccinated
with the adenoviral construct either by the systemic route or by application into the airways were protected against a
subsequent infection with a virulent strain of rabies virus. The efficacy of the replication-defective construct was far superior
to that of a well-characterized vaccinia rabies glycoprotein recombinant. q 1996 Academic Press, Inc.
INTRODUCTION induced a potent immune response including CD8/ cyto-
lytic T cells which destroyed the adenoviral antigen-ex-
Recombinant replication-defective adenoviruses are
pressing cells within 3 to 4 weeks (Yang et al., 1994). On
being developed for use in human gene therapy to re-
the other hand, immunodeficient SCID or RAG-20 mice or
place missing or faulty genes (Kozarsky and Wilson,
mice lacking functional CD8/ T cells showed persistent
1993). These adenoviruses based on human serotypes
expression of the adenovirus-encoded protein (Yang et
2 or 5 are rendered replication-defective by the deletion
al., 1994), confirming, in addition, that the construct per
of essential genes from the E1 locus, required for initia-
se had no cytopathic effects on infected cells.
tion of viral replication (Ginsberg et al., 1989). Further-
The strong immune response induced by the replica-
more, these constructs lack E3 expression which is not
tion-defective adenoviral recombinants led us to test this
essential for viral replication but which encodes a protein
construct for its potential as a vaccine carrier using the
that by down-regulating expression of major histocom-
well-defined murine rabies virus model. In this manu-patibility complex (MHC) antigens protects infected cells
script we describe the immune response to a rabies virus
from T-cell-mediated destruction (Ginsberg et al., 1989).
glycoprotein (G protein) expressing recombinant based
Recombinant replication-defective adenoviruses are con-
on the replication-defective human adenovirus type 5
sidered attractive candidates for human gene therapy;
(Ad5). The replication-defective construct was shown to
they can be readily grown and purified in large quantities
be highly efficacious in inducing protective immunity to
and they have the ability to express high levels of the
rabies virus.
transantigen in most cells, including those that are nondi-
viding. The replication-defective adenoviral constructs
MATERIALS AND METHODSlack many of the risks inherent to multiplying agents and
are thus well tolerated even at high doses. Experiments Animals
in animals as well as in humans using recombinant ade-
Female C3H/He and BALB/c mice were purchasednoviruses expressing a recombinant gene initially
from The Jackson Laboratory (Bar Harbor, ME). Outbredyielded promising results by showing high expression
ICR mice were purchased from Harlan Sprague– Dawleyof the adenovirus-encoded protein either in hepatocytes
(Indianapolis, IN). Mice were maintained at the Animalafter intravenous application or in cells of the airway
Facility of The Wistar Institute and used between 8 andmucosa after inhalation (Jaffe et al., 1992; Kozarsky et
12 weeks of age.al., 1993; Rosenfeld et al., 1992). But, expression was
transient in immunocompetent individuals, causing a mo- Cells
nonuclear inflammation concomitant with the loss of vi-
rally infected cells (Yang et al., 1994). Further studies Baby hamster kidney (BHK)-21 cells, L929 mouse fibro-
blasts, and HeLa cells were maintained in Dulbecco’sin inbred mice revealed that the adenoviral constructs
minimal essential medium (DMEM) supplemented with
10% fetal bovine serum (FBS), HEPES buffer, and antibiot-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (215) 898-3868. ics in a 10% CO2 incubator. 293 cells (Graham et al.,
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1977) were grown in DMEM with 10% FBS without HEPES plaques were harvested and tested for expression of the
rabies virus G protein as described below. One clonebuffer in a 5% CO2 incubator. A rabies virus-specific T
helper cell clone derived from spleens of C3H/He mice termed Adrab.gp was purified by two rounds of plaque
purification and used for further studies.immunized with the vaccinia rabies glycoprotein (VRG)
recombinant virus was cultured in weekly intervals on The adenoviral recombinants, Adrab.gp, the previously
described H5.010CMVlacZ expressing Escherichia coliirradiated syngeneic splenocytes pretreated with inacti-
vated rabies virus in DMEM supplemented with 2% FBS, lacZ (Wilson et al., 1994), and a replication-competent
adenovirus with E3 deleted [Ad5d17001] were grown on1006 M 2-mercaptoethanol, and 10% rat Concanavalin A
supernatant as a lymphokine source as described pre- 293 cells for 72 hr. Virus was recovered on the third
round of freeze – thawing. Cell-free supernatants eitherviously (Otvos et al., 1994). The B cell hybridoma cells
509-6, 1112-1, and 523-11 secreting antibodies to differ- were used directly or were further purified by CsCl den-
sity centrifugation. Viral stocks were titrated on 293 cellsent antigenic sites of the rabies virus G protein (509-6 to
site I, 1112-1 to site II, and 523-11 to site III; Wiktor and using a plaque assay.
Koprowski, 1978) were grown in DMEM supplemented
with 10% FBS. Ascitic fluid was prepared in BALB/c mice. Indirect immunofluorescence
L929 cells stably transfected with pSG5rab.gp1 vector,
expressing the rabies virus G protein as well as L929 Cells adherent to glass coverslips were infected for
48 hr with 1 plaque-forming unit (PFU) per cell of thecells transfected with pSV2neo, were maintained in 10%
DMEM supplemented with 10% FBS. These cell lines adenovirus recombinant. Cells were washed and treated
on ice for 60 min with a monoclonal antibody (mAb) toused as target cells for cell-mediated cytolysis assays
have been described in detail previously (Xiang and Ertl, rabies virus g protein. Cells were rinsed with phosphate-
buffered saline and then incubated for 60 min on ice with1994).
a fluorescein isothiocyanate (FITC)-labeled goat anti-
mouse immunoglobulin (Ig) antibody. Cells were rinsedViruses
again and analyzed by confocal microscopy.
Rabies virus of the Evelyn Rokitniki Abelseth (ERA)
strain was propagated on BHK-21 cells, purified, and Immunization and infection of mice
inactivated with betapropionolactone (BPL, inactivated
ERA: ERA-BPL) as described previously (Wiktor, 1973). Groups of ICR or C3H/He mice were injected subcuta-
neously (s.c.), orally, intranasally (i.n.), or upon anesthe-The challenge virus standard (CVS)-24 strain of rabies
virus, which is antigenically closely related to the ERA sia and surgical exposure of the trachea intratracheally
(i.t.) with the adenoviral constructs diluted in 100 to 150mlstrain but shows higher virulence in mice, was derived
from brain suspensions of infected newborn ICR mice of saline. VRG virus was given s.c. For protection studies,
groups contained five to eight mice; for most immunologi-(Wiktor et al., 1977). The VRG virus was propagated on
HeLa cells as described (Wiktor et al., 1984). cal studies, three to four mice were used per group. All
data give the results for sera or spleens pooled from theThe recombinant adenovirus expressing the rabies vi-
rus G protein of the ERA strain was constructed as fol- different groups. Mice were bled by retro-orbital puncture
in regular intervals after immunization to assess serumlows: the pAdCMVlacZ vector (Wilson et al., 1994), which
contains the lacZ gene under the control of the cytomega- antibody titers. Mice were challenged with 10 mean le-
thal doses (LD50) of CVS-24 virus given intramuscularlylovirus (CMV) promoter and a segment encoding the 5*
portion of Ad5 upstream of the CMV promoter and flank- (i.m.) into the masseter muscle; they were observed for
the following 3 weeks for symptoms indicative of a rabiesing E2 sequences (downstream of the CMV promoter),
was completely digested with NotI to remove the lacZ virus infection. Mice that developed complete bilateral
hindleg paralysis (proceeding death by 24 to 48 hr) weregene. The rabies virus G cDNA was purified from the
pSG5rab.gp vector (Burger et al., 1991) upon digestion euthanized for humanitarian reasons.
with Bgl II. Following blunt-ending (Klenow) the G gene
was cloned into the adenoviral vector. The appropriate Neutralization assay
orientation of the insert was confirmed by restriction en-
zyme mapping. The linearized plasmid was cotrans- Virus neutralizing antibody (VNA) titers were deter-
mined on BHK-21 cells using infectious ERA virus at 1fected into 293 packaging cells with an E3 deleted Ad5
DNA that had been digested with CLaI to remove the left PFU per cell (Dietzschold et al., 1987). Data are ex-
pressed as neutralization titers which are the reciprocalend of the adenovirus, rendering the DNA noninfectious.
In consequence, only products of homologous recombi- of the serum dilution resulting in a 50% reduction in the
number of infected cells. Samples were assayed in dupli-nation could produce infectious virus in 293 cells (which
had previously been stably transfected with the E1 gene cate in serial threefold dilutions starting with a dilution
of 1:5. Standard deviations were within 10% for any givenof human Ad5 to allow replication of the adenoviral con-
struct; Graham et al., 1977). Several recombinant viral experiment.
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Enzyme-linked immunosorbent assay (ELISA) 1, Adrab.gp virus-infected cells exhibited surface staining
with the antibody, while cells infected with the control con-
The ELISAs were conducted in 96-well microtiter struct expressing lacZ were negative.
plates coated with 2 mg per well of ERA-BPL virus or Further in vitro studies showed that the Adrab.gp con-
with purified adenovirus using an alkaline phosphatase- struct induced proliferation of a rabies virus G protein
conjugated goat anti-mouse Ig as second antibody as specific T helper cell clone in the presence of syngeneic,
described in detail (Xiang and Ertl, 1992). g-irradiated splenocytes (Fig. 2). In a separate experi-
ment, this T cell clone was shown to not proliferate to
T cell proliferation assay the H5.010 CMVlacZ construct (data not shown). Further-
more, mouse fibroblasts infected with the Adrab.gp re-
The T cell clone was cultured (2 1 104 cells/well) in combinant were rendered susceptible to lysis by rabies
96-well round-bottom microtiter plate wells with 5 1 105 virus G protein induced H-2 compatible cytolytic T cells
irradiated C3H/He splenocytes pretreated with different (Xiang et al., 1995). Together these in vitro experiments
antigen preparations in DMEM supplemented with 2% demonstrated that the Adrab.gp construct causes ex-
FBS and 1006 M 2-mercaptoethanol. Proliferation of the
pression of the rabies virus G protein in a form that is
cloned T cells was assessed 48 hr later by a 6-hr pulse
readily recognized by both rabies virus-specific antibod-
with 0.5 mCi of [3H]thymidine (Ertl et al., 1991).
ies and T cells of the helper and the cytolytic subset.
The Adrab.gp construct induces in mice a potentCell-mediated cytolysis
immune response including antibodies and cytolytic T
cells to rabies virusSplenocytes were harvested from immunized C3H/He
mice. Single cells were prepared and incubated at 6 1 In the next set of experiments mice were immunized
106 cells per well with 1 PFU per cell of the Adrab.gp with the Adrab.gp recombinant virus at several doses
recombinant virus in 1.6 ml of DMEM supplemented with using different routes of immunization. In some experi-
1006 M 2-mercaptoethanol and 2% FBS for 5 days in a ments an adenoviral construct expressing the lacZ gene
humidified 10% CO2 incubator. The effector cells were was used as a negative control, and the VRG recombi-
then cocultured with 51Cr-labeled L929 cells expressing nant was used as a positive control. Mice were bled 10
the rabies virus G protein upon stable transfection with to 14 days after a single immunization with the vaccine
the pSG5rab.gp vector at varied effector-to-target cell ra- and VNA titers were determined from the sera (Table
tios. To assess spontaneous release, 51Cr-labeled target 1). Adenovirus given s.c., i.t., or i.n. induced a potent
cells were incubated with medium; to determine maximal neutralizing antibody response if given at 106 PFU. Oral
release, target cells were cocultured with 10% sodium immunization with Adrab.gp or systemic immunization
dodecyl sulfate. Cell-free supernatants were harvested with H5.010CMVlacZ failed to induce a measurable anti-
4 hr later and radioactivity was measured. Percentage body response to rabies virus. The antibody responses
of specific lysis was calculated by using the following to different doses of the replication-defective Adrab.gp
formula (Yang et al., 1994): construct were clearly superior to the response induced
by the VRG recombinant. For example, the antibody titers
of mice inoculated with as little as 2 1 104 PFU of Ad-
rab.gp were more than 10 times higher than those of
Release in presence of effectors
0 spontaneous release
Maximal release 0 spontaneous release 1 100. mice infected with 2 1 106 PFU of VRG (Table 1).
To ensure that the antibody response was caused by
infection recombinant virus rather than by G protein frag-RESULTS
ments contaminating the virus-containing tissue culture
Antibodies and T cells to the rabies virus G protein supernatant used for immunization, mice were vacci-
recognize cells infected with the Adrab.gp construct nated with an equal dose of PFUs of unpurified and gradi-
ent purified recombinant adenovirus. Both groups of miceTo confirm that the Adrab.gp recombinant virus ex-
developed identical virus neutralizing antibody titers.presses the rabies virus G protein on infected cells in a
In addition to neutralizing antibodies, mice inoculatedform recognized by antibodies as well as T cell to rabies
s.c. with Adrab.gp virus developed rabies virus G protein-virus, a series of in vitro experiments were performed ini-
specific cytolytic T cells (Fig. 3) able to kill H-2 compatibletially. To assess the conformation of the G protein as ex-
L929 target cells stably transfected with a plasmid vector
pressed by the Adrab.gp virus, HeLa cells were infected
expressing the rabies virus G protein under the control
for 48 hr with 1 PFU of Adrab.gp virus per cell or as a
of the SV40 early promoter (Xiang and Ertl, 1994).
control with a similar adenoviral construct expressing lacZ.
The Adrab.gp construct induces protection againstCells were then stained by an indirect immunofluorescence
challenge with a lethal dose of rabies virusassay using mAbs (523-11, 509-6, and 1112-1) to different
conformation-dependent binding sites of the rabies virus G Mice immunized with the Adrab.gp construct or the
VRG virus were challenged 2 to 5 weeks after immuniza-protein. As shown for one of the antibodies (509-6) in Fig.
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FIG. 1. The Adrab.gp construct causes expression of the rabies virus G protein on the surface of infected cells. L929 fibroblasts, plated on glass
coverslips, were infected with 1 PFU of Adrab.gp (A) or of H5.010CMVlacZ (B). The following day cells were incubated for 60 min on ice with a
1:1000 dilution of ascitic fluid containing antibody 509-6. Cells were rinsed with phosphate-buffered saline and treated for 60 min with an FITC-
labeled goat anti-mouse Ig preparation. Staining was assessed under a confocal microscope.
tion with 10 LD50 of the virulent CVS-24 strain of rabies 103 PFU were protected, while all mice immunized with
virus given i.m. into the masseter muscle. As shown in only 102 PFU of the adenoviral construct or inoculated
Table 2, mice immunized with Adrab.gp s.c., i.t., or i.n. with the H5.010CMVlacZ control (21 106 PFU) construct
using doses ranging from 104 to 2 1 106 PFU were fully or with Adrab.gp per os developed a fatal rabies virus
protected against infection, 87% of mice inoculated with encephalitis within 10 days after infection. Mice vacci-
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FIG. 3. The Adrab.gp construct induces cytolytic T cells to the rabies
virus G protein. Groups of C3H/He mice were inoculated with 2 1 106
FIG. 2. The Adrab.gp construct induces in the presence of antigen PFU of Adrab.gp (j) or H5.010CMVlacZ (h). Splenocytes were har-
presenting cell proliferation of a rabies virus G protein T helper cell vested 14 days later and cocultured for 5 days with 1 PFU of Adrab.gp
clone. Irradiated C3H/He splenocytes plated at 5 1 105 cells per round- virus per cells. Activated lymphocytes were then tested at different
bottom microtiterplate well were incubated with 5 (
  
  ), 1 (‰, or 0.2 (j) effector to target cell ratios on H-2 compatible L929 cells stably
mg/ml of ERA-BPL virus or Adrab.gp at 1 (
  
  ), 0.1 (‰), and 0.01 (j) transfected with a rabies virus G protein-expressing vector
PFU per cell or as a negative control medium for 60 min at 377. Cloned (t.L929rab.gp, left) or as a control with a neomycin-expressing vector
T cells (2 1 104/well) were added. Cells were pulsed for 6 hr with 0.5 (t.L929.neo, right) in a 4-hr 51Cr-release assay. Data are means of tripli-
mCi of [3H]thymidine 48 hr later, harvested onto filtermats, and counted cates { SD.
in a b-counter. Data present counts per minute (cpm) { SD.
days previously were completely protected while morenated with VRG showed partial protection; the group re-
than half of the animals were protected as early as 7ceiving the highest dose, i.e., 2 1 106 PFU had a mortality
days after a single injection. Mice vaccinated 3 daysrate above 50%, rising to 90% in mice inoculated with
before challenge succumbed to the infection.2 1 104 PFU of VRG.
In the next set of experiments we tested the kinetic of
The Adrab.gp construct induces a B and T cell
the induction of protective immunity upon vaccination
response to rabies virus in spite of preexisting
with the Adrab.gp virus. Vaccination to rabies virus is in
immunity to adenovirus
general given postexposure, hence it is crucial for the
vaccine to induce a rapid immune response before the To test if preexisting immunity to adenoviral proteins
interferes with stimulation of a rabies G protein-specificrabies virus has reached the central nervous system. As
shown in Fig. 4, mice vaccinated with Adrab.gp virus 10
TABLE 2
TABLE 1
Adrab.gp Recombinant Induces Protective Immunity
to a Challenge with Rabies VirusaAdrab.gp Recombinant Induces Neutralizing Antibodies
to Rabies Virusa
Route of %
Vaccine Dose immunization MortalityRoute of VNA titer
Vaccine Dose immunization Time after immunization
Adrab.gp 2 1 106 s.c. 0
H5.010CMVlacZ 2 1 106 s.c. 90Adrab.gp 2 1 106 s.c. Day 10 3645
Adrab.gp 2 1 105 s.c Day 10 405 Adrab.gp 2 1 106 s.c. 0
Adrab.gp 2 1 105 s.c. 0Adrab.gp 2 1 104 s.c. Day 10 405
VRG 2 1 106 s.c. Day 10 45 Adrab.gp 2 1 104 s.c. 0
VRG 2 1 106 s.c. 56VRG 2 1 105 s.c. Day 10 15
VRG 2 1 104 s.c. Day 10 5 VRG 1 1 105 s.c. 71
VRG 2 1 104 s.c. 86None — — Day 10 5
Adrab.gp 104 s.c. Day 14 1215 None — — 100
Adrab.gp 104 s.c. 0Adrab.gp 103 s.c. Day 14 405
Adrab.gp 102 s.c. Day 14 5 Adrab.gp 103 s.c. 13
Adrab.gp 102 s.c. 100Adrab.gp 106 i.n. Day 14 1215
Adrab.gp 106 i.t. Day 14 3645 None — — 100
Adrab.gp 106 i.n. 0Adrab.gp 106 Per os Day 14 5
None — — 5 Adrab.gp 106 i.t. 0
Adrab.gp 106 Per os 100
None — — 100a Groups of ICR mice were immunized in three separate experiments
with the different vaccine constructs given at the indicated doses i.m.,
i.n., i.t., or per os. Mice inoculated into the trachea or i.n. were anesthe- a This table summarizes the results from four different experiments.
Mice immunized as described in legend to Table 1 were challengedtized prior to vaccination. Mice were bled 10 to 14 days later and serum
antibody titers to rabies virus were tested by a neutralization assay. 21 –28 days after immunization with 10 LD50 of rabies virus. Mice that
subsequently developed complete bilateral hindleg paralysis indicativeData are expressed as neutralization titers, which are the reciprocal
of the dilution resulting in a 50% reduction in the number of infected for a terminal rabies virus infection were euthanized for humanitarian
reasons. Survivors were observed for a total of 21 days.cells.
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FIG. 5. The cytolytic T cell response to rabies virus G protein express-
ing target cells upon immunization with Adrab.gp is only slightly re-
duced in animals immune to adenovirus. C3H/He mice were inoculated
with 106 PFU of replication-competent E3 deleted adenovirus. They
were boosted 3 weeks later with 106 PFU of Adrab.gp (h). Control mice
were inoculated with Adrab.gp only (j). Mice were sacrificed 4 weeks
later and upon restimulation with 1 PFU of Adrab.gp per cell tested
on a 4-hr 51Cr-release assay on L929 cells stably transfected with
pSG5rab.gp (a) or with pSV2neo (b). Data are expressed as the mean
FIG. 4. Mice were immunized with 106 PFU of Adrab.gp s.c. Immu- percentage specific lysis of triplicate results { SD.
nized mice were challenged 3 (L), 7 (h), and 10 (j) days after vaccina-
tion with 10 LD50 of rabies virus given i.m. Naive mice (1) served as
controls. Mice were observed for 4 weeks to record mortality. lysis compared to the control group. Nevertheless, ade-
novirus-immune mice still developed significant T cell
responses to the rabies virus G protein upon immuniza-immune response to the Adrab.gp construct, groups of
tion with Adrab.gp (Fig. 5).mice were inoculated with an E3 deleted adenovirus of
the human strain 5. Three weeks later mice were boosted
DISCUSSIONwith 106 PFU of Adrab.gp. Mice preimmunized with ade-
novirus developed VNA to rabies virus upon booster im- The advance of molecular biology allowing manipula-
munization with the Adrab.gp construct; titers were tion of genetic material has benefited both the develop-
slightly lower when compared to those in control mice ment of vaccines and more recently the generation of
that had only received the Adrab.gp construct (Table 3), reagents suitable for gene therapy. In some instances,
indicating that antibodies to adenoviruses marginally in- these two fields that fundamentally differ in their goals,
hibit the B cell response to proteins expressed by adeno- one aiming at the induction of a protective immune re-
virus recombinants. When tested in comparison to a ref- sponse to pathogens, the other at the permanent replace-
erence serum provided by the World Health Organization, ment of faulty or missing genes, have been shown to
sera from preimmune (both doses of adenovirus) or naive overlap. For example, i.m. transfer of plasmid DNA was
mice were shown to have titers of 40 IU to rabies virus. shown by gene therapists to result in long-term expres-
Protection to rabies virus is correlated to antibody titers sion of vector-encoded sequences (Wolff et al., 1990,
and 2 IU are considered sufficient to protect against a 1992); immunologists subsequently modified the ap-
severe challenge. Preimmunity to adenovirus does, thus, proach by using plasmids encoding foreign antigens
not impair the ability of the Adrab.gp vaccine to elicit such as viral proteins and demonstrated induction of
protective immunity. Similar data were obtained for the protective immune responses, opening the new field of
stimulation of cytolytic T cells to rabies virus-infected DNA vaccines (Ulmer et al., 1993). Similarly, in this manu-
cells, and preimmune animals showed somewhat lower script, a construct based on an E1 and E3 deleted Ad5
that was initially developed for gene therapy to cure dis-
eases such as cystic fibrosis (Rosenfeld et al., 1992) wasTABLE 3
found to be highly immunogenic and thus, in its current
The Effect of Preexisting Immunity to Adenovirus on the Rabies
form, unsuitable for its intended purpose. The potent im-VNA Response to the Adrab.gp Vaccinea
mune response elicited by the replication-defective ade-
Preimmunization Immunization VNA titer novirus leading to CD8/ T-cell-mediated elimination of
infected cells within 3 to 4 weeks (Yang et al., 1994) led
None 106 PFU Adrab.gp 3.645 us to test its potential use as a vaccine carrier. The
105 PFU Ad5d17001 106 PFU Adrab.gp 3.645
recombinant adenovirus expressing the rabies virus G106 PFU Ad517001 106 PFU Adrab.gp 1.215
protein under the control of the CMV early promoter inNone None 5
a form that was readily recognized by antibodies to con-
a Groups of C3H/He mice were immunized with 105 or 106 pFU of a formation-dependent epitopes as well as by activated
replication-competent adenovirus human serotype 5 that had the E3 rabies virus G protein-specific T cells induced by either
gene deleted. Mice were injected 4 weeks later with 106 PFU of Ad- live rabies virus or the VRG recombinant was found torab.gp. Control mice were only injected with Adrab.gp (106 PFU). Mice
be extraordinarily efficacious at inducing protective im-were bled 12 days later and neutralizing antibody titers were deter-
mined. munity to challenge with rabies virus; mice immunized
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with as little as 104 PFU of Adrab.gp were completely nant adenoviruses have also been previously used as
vaccine carriers. One of these recombinants expressingprotected against rabies. Partial protection was already
seen 7 days after immunization. The efficacy of this repli- the rabies virus G protein was shown to induce protective
immunity in animals to challenge with rabies virus (Pre-cation-defective construct was thus far superior com-
pared to that of the previously described VRG vaccine vec et al., 1990). The efficacy of this vaccine was compa-
rable to that observed with a vaccinia recombinant;that is currently being used for oral wildlife immunization
(Brochier et al., 1994). The VRG virus has previously been doses above 106 PFU of this replication-competent virus
were required to induce complete protection to viral chal-shown to replicate for at least 48 hr in infected mice
(United States Department of Agriculture, Animal and lenge.
The Adrab.gp vaccine was found to be efficaciousPlant Health Inspection Service, 1992), thereby increas-
ing the antigenic load by several orders of magnitude. upon systemic application or administration into the air-
ways. Unlike the previously described replication-compe-The finding that the replication-defective Adrab.gp con-
struct was the more efficacious of the two vaccines was tent adenovirus recombinants immunity could not be elic-
ited upon oral immunization (Prevec et al., 1990).thus unexpected. Other parameters such as appropriate
presentation of antigen by professional antigen present- Adenoviruses cause early childhood infections that are
manifested by mild respiratory symptoms. Most childrening cells or cytokine release by infected cells might influ-
ence the magnitude of the immune response. Pox viruses become seropositive within their first year of life, which
might potentially interfere with active immunization usingare known to subvert the immune system by encoding a
protein that mimics the IL-1 receptor and an additional a vaccine based on human adenoviruses. Data pre-
sented here show only a small reduction of the immuneprotein that inhibits the enzyme that cleaves the IL-1b
precursors protein (Marrack and Kappler, 1994). Wild- response to the rabies virus G protein in mice that had
recently been infected with a high dose of replication-type adenoviruses evade immune surveillance by down-
regulating MHC expression, a function of products of the competent adenovirus. Further studies are needed to
establish the specificity and the kinetics of this inhibition.E3 locus (Ginsberg et al., 1989) deleted in all of the vi-
ruses used in this study. In addition to the antigenic
load, the kinetics of antigen expression might affect the ACKNOWLEDGMENTS
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